Key statistics
As of last trade, Amplia Therapeutics Ltd (ATX:ASX) traded at 0.12, 144.90% above the 52 week low of 0.049 set on May 30, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.12 |
|---|---|
| High | 0.12 |
| Low | 0.12 |
| Bid | 0.12 |
| Offer | 0.125 |
| Previous close | 0.125 |
| Average volume | 417.95k |
|---|---|
| Shares outstanding | 513.07m |
| Free float | 434.91m |
| P/E (TTM) | -- |
| Market cap | 64.13m AUD |
| EPS (TTM) | -0.0204 AUD |
Data delayed at least 20 minutes, as of Feb 16 2026 03:31 GMT.
More ▼
Announcements
- Amplia Therapeutics Announces Opening of US Sites for Amplicity Pancreatic Cancer Trial
- Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025
- NARMAFOTINIB Large-Scale Manufactre Complete
- ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
- Amplia Therapeutics to Present at 2026 ASCO Gastrointestinal Cancers Symposium
- Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
- Additional Confirmed Response Reported as Part of Amplia Investor Presentation
- Key Narmafotinib Patent Granted in the U.S.
More ▼
